http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease
-
Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results
-
Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018
-
Anavex Life Sciences (AVXL) Begins Phase 2 Study of ANAVEX2-73 in Parkinson’s Disease Dementia; Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome
-
Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett Syndrome
-
Anavex Life Sciences to Present at the 30th Annual ROTH Conference
-
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
-
Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference
-
Anavex Life Sciences Strengthens Management Team and Board of Directors
-
Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference
-
Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results
-
Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018
-
Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference
-
Anavex Life Sciences (AVXL) Announces Potential Normalization of Hypertension with ANAVEX2-73 Published in The Journal of Clinical Hypertension
-
Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX®2-73 Published in The Journal of Clinical Hypertension
-
Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs
-
Anavex Life Sciences (AVXL) Says Newly Published Data on AD Research Demonstrate Neuroprotective Features of Sigma-1 Receptor
-
Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor
-
Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC
-
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting
-
Anavex Life Sciences (AVXL) Presents Additional Data on ANAVEX2-73 at Conference
-
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conference
-
Anavex Life Sciences (AVXL) Announces New Data Related to MS Presented at ECTRIMS-ACTRIMS Meeting
-
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
-
Anavex Life Sciences (AVXL) Reports PK and PD Data from Phase 2a Trial of ANAVEX 2-73 in Mild-to-Moderate AD
-
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET
-
Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
-
Anavex Life Sciences (AVXL) Reports U.S. Patent for Composition of Matter Covering ANAVEX 2-73
-
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73
-
Anavex Reports Fiscal Third Quarter 2017 Financial Results
-
Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
-
Anavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference
-
Anavex Life Sciences (AVXL) Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders
-
Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome: Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
-
Anavex Reports Fiscal Second Quarter 2017 Financial Results
-
Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs
-
Anavex Life Sciences (AVXL) Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor at AD/PD Meeting
-
Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor
-
Anavex Life Sciences (AVXL) Announces Order of Dismissal of the Appeal in the Cortina v. Anavex Case
-
Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit
-
Anavex Life Sciences (AVXL) to Present at AD/PD Conference
-
Anavex Life Sciences to Present at the 13th International Conference on Alzheimer's and Parkinson's Diseases AD/PD™ 2017
-
Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference
-
Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference
-
Anavex Life Sciences (AVXL) Appoints Peter Donhauser to Board of Directors
-
Anavex Life Sciences Strengthens Board of Directors
-
Anavex Life Sciences’ CEO Joins BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”
-
Anavex Reports Fiscal First Quarter 2017 Financial Results
-
Anavex Life Sciences to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
-
Anavex Life Sciences (AVXL) Receives 600K Grant to Commence Phase 2 Trial in 2017

